| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Verastem, Inc.$5.53
+0.08 (+1.48%)
C 50Pipeline Score Fair Value Biotech · Clinical
Market Cap
372.58 M
EPS
-2.51
P/E Ratio
-
Value Trade
11.99 M
SEC Financials
Q1 2026Dilution Risk
Revenue
18.67 M
R&D Expenses
38.22 M
Operating CF
-52.12 M
Total Assets
227.81 M
Total Liabilities
146.03 M
Equity
81.78 M
D/E Ratio
12,345
-9.79 %
Week
-30.38 %
1 Month
-27.52 %
3 Month
-56.24 %
6 Month
-89 %
5 Year
-96.79 %
All Time
Cash Data
Cash Position
181.68 M
Monthly Burn
17.37 M
Runway
8.6 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
2.99 M
52 Week Range
4 - 11.25
% held by Insiders
9.72 %
% held by Institutions
92.89 %
Enterprise Value
276.38 M
Total Shares
87.90 M
Short %
27.45 %
Float Shares
81.92 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Verastem, Inc.
474Total events
18Upcoming
135Tier-1 (high impact)
2011 – 2040Coverage
Upcoming catalysts 18
Q4 2026
T2Trial Initiation
Initiate single-agent and combination Phase 2 registration-directed studies in 2H 2026
Q4 2026
T2Product Launch
AVMAPKI FAKZYNJA CO-PACK franchise expected to be self-sustaining in 2H 2026
Sep 2032
T2Patent Granted
VS-6766 composition of matter patent expires Sept 2032; method of making patent expires May 2038; combination with defactinib patent expires 2041-2042 if issued
TBD
T2Trial Initiation
RAMP 205 trial evaluating avutometinib plus defactinib with chemotherapy in first-line pancreatic cancer
TBD
T1FDA Approval
FDA approval of avutometinib and defactinib for LGSOC triggers $25M tranche from Oberland facility
Event history 456
Q3 2026
◆Trial InitiationVS-7375Trial
Initiate single-agent and combination randomized registration-directed studies 2H 2026 into 2027
KRAS G12D solid tumorssource ↗
Jun 17, 2026
▲Full ResultsAvutometinibApprovedClinical Data
Positive updated results from RAMP 205 evaluating avutometinib plus defactinib in combination with chemotherapy in first-line metastatic pancreatic cancer
first-line metastatic pancreatic cancersource ↗
Jun 16, 2026
▲First Patient DosedVS-7375Trial
First patient dosed in Phase 2 registration-directed trial of VS-7375
KRAS G12D-mutated metastatic pancreatic cancersource ↗
Jun 15, 2026
◆Oral PresentationVS-7375Presentation
Investor conference call to report updated data and progress
KRAS G12D-mutated solid tumorssource ↗
Jun 2026
●Trial InitiationVS-7375Trial
FPI expected in mid-2026 for VS-7375 in 2L+ CRC combination cohorts
KRAS G12D-mutated metastatic colorectal cancersource ↗
May 26, 2026
May 12, 2026
May 8, 2026
▲FDA ApprovalAvutometinibApprovedFDA Decision
One-year anniversary of FDA approval of AVMAPKI FAKZYNJA CO-PACK
KRAS-mutated recurrent low-grade serous ovarian cancersource ↗
May 7, 2026
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Business Update Conference Call
May 7, 2026
▲Enrollment CompleteAvutometinibApprovedTrial
Completed enrollment of 29 patients in expansion phase of RAMP 205
first-line metastatic pancreatic cancersource ↗
Drug Pipeline Intelligence
C50
Pipeline Score $664M
Pipeline ValueFair Value
Valuation Signal9
Drugs Scored1.8x
rNPV / MCap Top 75%
Micro Cap (rank 229 of 911)
Percentile RankVerastem, Inc. carries a moderate pipeline score (50/100), with $3.0B risk-adjusted pipeline value, led by Duvelisib in COVID-19 (Phase 2), across $185B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duvelisib Small molecule | COVID-19 | Phase 2 | NCT04372602 | 40% | $1.0B | COMPLETED | 75 | - | - | Mar 2, 2022 | - | Mar 6, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
avutometinib and defactinib BreakthroughAcceleratedOrphan | recurrent low-grade serous ovarian cancer (LGSOC) and other KRAS-mutated tumors | Phase 3 | 2026-05-07 | overall response rate: 83.3% (10/12); partial response: 10 (83.3); stable disease: 2 (16.7); progressive disease: 0; disease control rate: 92% (11/12) Read More | Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A Y 2 0 2 6 2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among other Read More | |
avutometinib and defactinib BreakthroughAcceleratedOrphan | recurrent low-grade serous ovarian cancer (LGSOC) and other KRAS-mutated tumors | Phase 3 | 2026-05-07 | overall response rate: 83.3% (10/12); partial response: 10 (83.3); stable disease: 2 (16.7); progressive disease: 0; disease control rate: 92% (11/12) Read More | Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A Y 2 0 2 6 2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among other Read More | |
avutometinib and defactinib BreakthroughAcceleratedOrphan | recurrent low-grade serous ovarian cancer (LGSOC) and other KRAS-mutated tumors | Phase 3 | 2026-05-07 | overall response rate: 83.3% (10/12); partial response: 10 (83.3); stable disease: 2 (16.7); progressive disease: 0; disease control rate: 92% (11/12) Read More | Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A Y 2 0 2 6 2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among other Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VSTM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VSTM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VSTMVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
Verastem Oncology has announced positive updated results from the RAMP 205 study, which evaluated the combination of Avutometinib and Defactinib alongside standard chemotherapy for first-line treatment of metastatic pancreatic cancer. The findings indicate a promising efficacy of this combination therapy, potentially enhancing treatment options for patients.
Read more →VSTMVerastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
Verastem Oncology has initiated the TARGET-D 201 Phase 2 trial by dosing the first patient with VS-7375, an oral KRAS G12D inhibitor. This trial aims to evaluate the efficacy of the treatment in patients with KRAS G12D-mutated metastatic pancreatic cancer. The study is registration-directed, indicating its importance in the drug approval process.
Read more →VSTMVerastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
Verastem Oncology is set to host an investor conference call to discuss updated data and progress on their VS-7375 oral KRAS G12D inhibitor within the TARGET-D clinical program. The event aims to provide insights into the ongoing developments and future directions of this therapeutic approach.
Read more →VSTMVerastem Oncology to Present at Jefferies Healthcare Conference
Verastem Oncology is scheduled to present at the Jefferies Healthcare Conference. This event will provide an opportunity for the company to share insights and updates regarding its oncology pipeline. Further details about the presentation or specific topics to be discussed have not been disclosed.
Read more →VSTMVerastem Oncology Appoints Michael P. Bailey to its Board of Directors
Verastem Oncology has appointed Michael P. Bailey to its Board of Directors. This strategic addition aims to enhance the company's leadership and governance. Bailey's experience is expected to contribute positively to Verastem's future endeavors.
Read more →VSTM▼ -5.1%on this news
Verastem Oncology to Present at Upcoming Investor Conferences
Verastem Oncology is scheduled to present at upcoming investor conferences. The details regarding the specific conferences or the content of the presentations were not disclosed in the article. This announcement indicates the company's ongoing engagement with investors and the market.
Read more →VSTM▼ -5.8%on this news· ran to -23% by day 3shared move
Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A Y 2 0 2 6 2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among other
The presentation discusses advancements in developing novel therapies targeting RAS/MAPK pathway-driven cancers, with a focus on two key drugs: avutometinib and defactinib. Early trial data highlights an 83.3% overall response rate for the combination therapy in patients. The company has secured financial backing of up to $150 million, contingent upon achieving set milestones. Additional clinical development efforts are aimed at expanding treatment options for recurrent low-grade serous ovarian cancer (LGSOC) and other KRAS-mutated tumors.
Read more →VSTM▼ -5.8%on this news· ran to -23% by day 3shared move
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem Oncology has reported its financial results for the first quarter of 2026. The company also highlighted recent business updates, although specific details were not disclosed in the article. This report serves as an overview of the company's current financial standing and strategic direction.
Read more →VSTMVerastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Verastem Oncology has launched the Reimagine campaign to raise awareness about AVMAPKI® FAKZYNJA® CO-PACK, the first FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer. This initiative aims to educate healthcare professionals and patients about the treatment options available for this specific cancer type. The campaign reflects Verastem's commitment to advancing care for patients with RAS/MAPK pathway-driven cancers.
Read more →VSTMVerastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
Verastem Oncology has announced a conference call scheduled for May 7, 2026, to discuss its first quarter financial results and business updates. The call will be accessible via a live audio webcast, with a replay available afterward. The company focuses on developing treatments for RAS/MAPK pathway-driven cancers.
Read more →VSTM▼ -5%on this news
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
Verastem Oncology has announced positive two-year median follow-up data from its Phase 2 RAMP 201 clinical trial. The trial evaluated the AVMAPKI® FAKZYNJA® combination therapy in patients with recurrent low-grade serous ovarian cancer. The results will be presented at the Society of Gynecologic Oncology's annual meeting.
Read more →VSTMVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2026
Verastem Oncology has announced the grant of 141,000 restricted stock units to eleven new employees as part of an inducement under Nasdaq Listing Rule 5635(c)(4). The stock units will vest over a four-year period, with 25% vesting on the one-year anniversary of hire. This initiative aims to enhance the company's workforce in developing treatments for RAS/MAPK pathway-driven cancers.
Read more →VSTMVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This move is part of their ongoing strategy to enhance their workforce and align with regulatory requirements. Further details on the specific grants or their intended impact were not disclosed.
Read more →VSTMVerastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers
Verastem Oncology announced that new long-term data from the Phase 2 RAMP 201 trial will be presented at the Society of Gynecologic Oncology 2026 Annual Meeting. The data focuses on the efficacy and safety of the AVMAPKI™ FAKZYNJA™ combination therapy for recurrent low-grade serous ovarian cancer. The presentation aims to reinforce previous findings and contribute to the clinical understanding of this treatment.
Read more →VSTMVerastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
Verastem Oncology announced that multiple abstracts related to its investigational drug VS-7375 have been accepted for presentation at the AACR Annual Meeting 2026. The preclinical data demonstrates that VS-7375, a dual ON/OFF KRAS G12D inhibitor, achieves significant tumor regression in models of pancreatic, lung, and colorectal cancers. The company aims to advance its clinical development for patients with RAS/MAPK pathway-driven cancers.
Read more →VSTM▲ +5.9%on this news
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
Verastem Oncology reported strong financial results for Q4 and full year 2025, highlighted by the FDA approval of AVMAPKI FAKZYNJA CO-PACK. The company achieved $17.5 million in net product revenues for Q4 2025 and plans to advance clinical trials for VS-7375, a promising KRAS G12D inhibitor. Despite a net loss of $32.9 million, the company maintains a solid cash position to support ongoing operations.
Read more →VSTMDelivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A R C H 2 0 2 6 2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among o
VSTM reported positive Q4 and full-year results for 2025, highlighting a robust cash position of $205 million. The company is advancing clinical programs such as the AVMAPKI FAKZYNJA CO-PACK franchise, which is expected to become self-sustaining by the second half of 2026. Their ongoing Phase 3 trial may significantly expand treatment indications in recurrent LGSOC. Additionally, promising preliminary efficacy data for VS-7375 in KRAS G12D solid tumors was reported, bolstering VSTM's position in oncology development.
Read more →VSTMVerastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Verastem Oncology has announced a conference call scheduled for March 4, 2026, to discuss its fourth quarter and full year 2025 financial results. The call will provide updates on the company's business and will be accessible via phone and webcast. Verastem focuses on developing medicines for RAS/MAPK pathway-driven cancers.
Read more →VSTM▼ -7.5%on this news
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
Verastem Oncology provided preliminary revenue estimates for the fourth quarter and full year of 2025, projecting approximately $17.5 million and $30.9 million, respectively, following FDA approval of AVMAPKI FAKZYNJA CO-PACK. The company plans to advance its clinical programs, particularly VS-7375, a KRAS G12D inhibitor. Leadership will participate in a fireside chat at the Guggenheim Emerging Outlook Conference in February 2026.
Read more →VSTMVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 12, 2026
Verastem Oncology has announced the grant of stock options and restricted stock units to new employees as part of an inducement under Nasdaq Listing Rule 5635(c)(4). A total of 73,000 stock options and 218,265 restricted stock units were awarded to enhance employee retention. The options have an exercise price of $6.88 per share, reflecting the company's commitment to its workforce.
Read more →VSTMDelivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION JANUARY 2026 2 FORWARD - LOOKING STATEMENTS This presentation includes forward - looking statements about, among other things, Veras
Verastem Oncology presented its forward-looking statements about its therapeutic programs targeting RAS/MAPK pathway-driven cancers. The company's lead product, AVMAPKIFAKZYNJACO-PACK, aims to address KRAS mutant recurrent low-grade serous ovarian cancer. Collaborations with GenFleet Therapeutics and ongoing clinical trials highlight the company's strategic focus. However, there are notable risks including regulatory approval challenges and the complexities of successful trial enrollment and commercialization.
Read more →VSTMVerastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Verastem Oncology announced the discontinuation of the RAMP 203 Phase 1/2 clinical trial for advanced KRAS G12C-mutant non-small cell lung cancer. The decision follows interim data evaluation and aims to redirect resources towards the development of VS-7375, a promising oral KRAS G12D inhibitor. Patients currently enrolled can continue treatment at the investigator's discretion.
Read more →VSTMVerastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth John Johnson, current board member, appointed to chairman of the board Michael Kauffman, MD, PhD, lead director since 2016, appoint
Verastem Oncology has announced a strategic transition plan aimed at accelerating its growth, featuring leadership changes such as the appointment of Michael Kauffman as President of Development and John Johnson as Chairman of the Board. This transitions comes as the company successfully completes additional patient enrollment for the Phase 3 RAMP 301 trial in recurrent low-grade serous ovarian cancer (LGSOC). The company anticipates reporting topline data from this trial in mid-2027 and continues to focus on commercializing its products, including AVMAPKI FAKZYNJA CO-PACK, which has already received FDA approval. The leadership shifts are expected to further strengthen Verastem's initiatives in drug development and market presence.
Read more →VSTM▲ +21.1%on this news
PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution. The following table sets forth estimates of the various expenses, other than any underwriting discounts and commissions
The document provides information about the estimated expenses associated with the issuance and distribution of securities for VSTM. It outlines various costs including registration fees, printing, legal and accounting fees, and miscellaneous expenses. The total estimated expenses amount to $400,000, excluding any underwriting discounts and commissions. This information likely pertains to the company's preparations for securities registration but does not indicate any significant developments or adverse events.
Read more →VSTM▼ -20.1%on this news
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates Achieved AVMAPKI FAKZYNJA CO-PACK net product revenue of $11.2 million VS-7375 cleared first two monotherapy dose leve
Verastem Oncology reported its third-quarter financial results for 2025, highlighting a net product revenue of $11.2 million from the launch of AVMAPKI FAKZYNJA CO-PACK. The company also announced successful clearance of the first two monotherapy dose levels of VS-7375, with no significant toxicities observed. Initiated patient enrollment for VS-7375 in combination with cetuximab marks an important step in its clinical pipeline. The financial review shows an increase in operating expenses and a substantial net loss, but the company maintains a strong cash position.
Read more →VSTMVerastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors First two monotherap
Verastem Oncology has announced encouraging preliminary data from its Phase 1/2a trial evaluating VS-7375, a KRAS G12D (ON/OFF) inhibitor, in patients with specific solid tumors. The trial has successfully cleared initial dose levels without any dose-limiting toxicities reported. Notably, some patients have shown promising anti-tumor activity, including those with advanced pancreatic ductal adenocarcinoma. Enrollment for a combination therapy with cetuximab has also been initiated, indicating the company's ongoing commitment to addressing unmet needs in cancer treatment.
Read more →VSTM▼ -13%on this newsshared move
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma GFH375 resulted in a 41%
Verastem Oncology announced positive updated data from a Phase 1/2 monotherapy study of GFH375 (VS-7375) for patients with advanced KRAS G12D mutant pancreatic ductal adenocarcinoma. The study showed an overall response rate of 41% and an overall survival rate of 92.2% at four months. Additionally, 91.5% of patients experienced a reduction in tumors, while the safety profile demonstrated manageable adverse events with a low rate of treatment discontinuation. These results were presented at the ESMO Congress 2025, highlighting the therapeutic potential of KRAS G12D inhibition.
Read more →VSTM▼ -5%on this news
Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers Corporate Presentation | September 2025 2 Forward - Looking Statements This presentation includes forward - looking statements about, among other things, Ver
Verastem Oncology presented their corporate strategy focused on novel therapies targeting RAS/MAPK pathway driven cancers. The discussion included forward-looking statements about various product candidates and upcoming clinical trials, especially in relation to KRAS mutant recurrent Low-Grade Serous Ovarian Cancer. However, the company acknowledged significant risks affecting the commercialization of their products, including competition and potential funding issues. Overall, while there are promising developments, uncertainties remain regarding successful outcomes.
Read more →VSTMVerastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer GFH375 demons
Verastem Oncology announced positive late-breaking data from a Phase 1/2 study of GFH375 (VS-7375) in advanced non-small cell lung cancer, showing an overall response rate of 68.8% at the recommended dose. This data will be presented at the IASLC 2025 World Conference on Lung Cancer. The study also reported a disease control rate of 93.8%, along with specific adverse events relating to the treatment. The findings reinforce the potential of GFH375 as a promising therapy targeting KRAS G12D mutations in lung cancer.
Read more →VSTM▼ -19.9%on this news
Verastem Oncology R&D Investor Event ASCO 2025
Verastem Oncology held an R&D Investor Event to discuss their ongoing clinical programs, including the anticipated launch of avutometinib and defactinib for Low-Grade Serous Ovarian Cancer. The presentation included forward-looking statements regarding the timing of trials and collaborations, particularly with GenFleet Therapeutics. However, investors were warned about various risks including uncertainties in trial outcomes, regulatory approvals, and the competitive landscape affecting commercialization efforts.
Read more →VSTM▼ -19.9%on this news
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor In the study in China, GFH375 demonstrated an ORR of 52% in pa
Verastem Oncology announced updated data from the Phase 1 study of GFH375 (VS-7375), revealing an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and an ORR of 42% in non-small cell lung cancer. The study included 62 patients, with promising results regarding the drug's efficacy and safety profile. Verastem plans to initiate a Phase 1/2a trial in the U.S. to further evaluate the drug's potential. The data was presented at the ASCO Annual Meeting in Chicago.
Read more →VSTMVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma Select
Verastem Oncology has reported positive results from the updated RAMP 205 Phase 1/2 trial evaluating the combination of avutometinib and defactinib with chemotherapy in frontline metastatic pancreatic ductal adenocarcinoma (PDAC). The trial revealed an overall response rate (ORR) of 83% in the dose level 1 cohort, with plans for a registrational Phase 3 study set to commence in 2026. The company is also preparing to present further data on its candidate VS-7375 at the upcoming ASCO Annual Meeting. Overall, these findings indicate strong potential for the treatment strategy in advanced cancers.
Read more →VSTMFDA Approves the AVMAPKI FAKZYNJA Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer AVMAPKI plus FAKZYNJA to be commercially available by presc
The FDA has granted accelerated approval for the AVMAPKI FAKZYNJA CO-PACK as the first treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer. This approval is based on the positive results from the Phase 2 RAMP 201 study, which indicated a 44% overall response rate among participants. The new therapy, co-packaged as a convenient oral medication, is set to be commercially available in the U.S. shortly. Continued approval will depend on further verification of clinical benefits through ongoing trials.
Read more →VSTMVerastem Oncology Announces $75 million Private Placement BOSTON-(BUSINESS WIRE)
Verastem Oncology has announced a private placement of approximately $75 million, consisting of $24 million in common stock and $51 million in pre-funded warrants. The funds are earmarked for the potential launch of the company's candidate drugs, avutometinib and defactinib, in treating recurrent low-grade serous ovarian cancer. The closing of the placement is anticipated on or about April 28, 2025. The offering will be led by RTW Investments, with several other institutional investors participating. Proceeds will also support ongoing clinical research and operational needs.
Read more →VSTMDelivering Novel Therapies for RAS/MAPK Pathway Driven Cancers Corporate Presentation | March 2025 2 Forward - Looking Statements This presentation includes forward - looking statements about, among other things, Veraste
Verastem Oncology's corporate presentation discusses its advancements in therapies targeting RAS/MAPK pathway-driven cancers. The presentation details potential future launches of its treatment candidates, particularly avutometinib and defactinib, and ongoing collaborations with GenFleet Therapeutics. It also outlines various risks associated with clinical trials, regulatory uncertainties, and market competition that could impact the success of its product candidates. Overall, while there are positive developments, challenges remain that could affect progress and commercialization.
Read more →VSTMDelivering Novel Therapies for RAS/MAPK Pathway Driven Cancers January 2025 Corporate Presentation 2 Disclaimers Forward-Looking Statements This presentation includes forward-looking statements about, among other things,
VSTM is focusing on advancing novel therapies targeting RAS/MAPK-driven cancers, particularly through the combination of Avutometinib and Defactinib for recurrent low-grade serous ovarian cancer (LGSOC). The treatment has shown promising results in clinical trials, leading to FDA Breakthrough Designation. However, the trial also observed some adverse events and challenges with lower dosing regimens which were deemed ineffective.
Read more →VSTM▲ +40.9%on this news· ran to +83% by day 3
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 C
Verastem Oncology has announced a significant debt refinancing deal with Oberland Capital, providing up to $150 million, alongside a strategic partnership with IQVIA to support the commercialization of their investigational drug combination for recurrent KRAS mutant low-grade serous ovarian cancer. This partnership aims to leverage IQVIA's infrastructure to facilitate the product launch anticipated in mid-2025. The refinancing and equity investment are projected to enhance Verastem's financial position, providing a cash runway beyond expected FDA approval, which has a PDUFA date set for June 30, 2025.
Read more →VSTM▼ -20.1%on this news
In Collaboration With Efficacy and Safety of Avutometinib Defactinib in Recurrent Low - Grade Serous Ovarian Cancer: Primary Analysis of ENGOT - OV60/GOG - 3052/RAMP 201 Susana N. Banerjee , Carol Aghajanian, Els Van Nie
The primary analysis of the ENGOT-OV60/GOG-3052/RAMP 201 trial evaluated the efficacy and safety of the combination of avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC). Avutometinib acts as an oral RAF/MEK inhibitor, while defactinib is a FAK inhibitor, targeting the adaptive resistance mechanisms in the RAS/MAPK pathway. The findings suggest that this combination may offer new hope for patients with LGSOC, a cancer subtype with limited treatment options and high rates of treatment discontinuation due to toxicity. The results have garnered attention, highlighting the need for innovative therapies in this area.
Read more →VSTMDelivering Novel Therapies in RAS/MAPK Pathway Driven Cancers June 2024 Corporate Presentation 2 Disclaimers F orward - Looking Statements This presentation includes forward - looking statements about, among other things
Verastem Oncology shared a corporate presentation outlining the progress and future plans concerning its drug candidates, especially focusing on the rolling NDA submission for the combination of avutometinib and defactinib in treating low-grade serous ovarian cancer. The company highlighted collaborations with GenFleet Therapeutics and detailed multiple clinical trials under consideration. However, various risks and uncertainties regarding development timelines, commercialization success, and clinical results were emphasized, underscoring the inherent unpredictability of the biotech landscape.
Read more →VSTM▼ -66.2%on this news
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-
Verastem Oncology has initiated a rolling submission for a New Drug Application to the FDA, seeking accelerated approval for the combination of avutometinib and defactinib for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer. The company plans to leverage data from the ongoing RAMP 201 trial, aiming for completion in the second half of 2024. The FDA has previously granted Breakthrough Therapy Designation for this combination, emphasizing potential benefits over available treatments. Currently, no FDA-approved treatment options exist specifically for this patient population.
Read more →VSTMVerastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pan
Verastem Oncology has reported positive interim results from its RAMP 205 trial, where 83% of patients achieved a confirmed partial response using a combination of avutometinib, defactinib, gemcitabine, and Nab-paclitaxel for treating metastatic pancreatic cancer. The trial also identified a dose-limiting toxicity, but the affected dose cohort was later cleared for additional patients. Results are set to be presented at the ASCO Annual Meeting on June 1, 2024, highlighting the potential of targeting the RAS/MAPK pathway in treatment strategies. The company is moving forward with the trial to determine the recommended Phase 2 dose amidst increasing acknowledgment of the urgent need for new therapies in this challenging cancer type.
Read more →VSTMDelivering Novel Therapies in RAS/MAPK Pathway Driven Cancers April 2024 Corporate Presentation 2 Disclaimers Forward - Looking This presentation includes forward - looking statements about Verastem Oncology's programs a
Verastem Oncology's April 2024 corporate presentation outlines advancements in their RAS/MAPK pathway-driven cancer therapies. The company reported strong progress in 2023 and is on track to deliver its first approved therapy for low-grade serous ovarian cancer, with a study showcasing promising data. Ongoing trials and a planned rolling NDA for Accelerated Approval highlight its strategic objectives. However, the presentation also addresses inherent risks and uncertainties linked to clinical trial outcomes and regulatory processes.
Read more →VSTM▲ +7.1%on this news
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
Verastem Oncology announced its strategic priorities for 2024, focusing on advancing their pipeline of treatments for RAS pathway-driven cancers. Key plans include the submission of a New Drug Application for the combination of Avutometinib and Defactinib for recurrent Low-Grade Serous Ovarian Cancer in the first half of 2024. Additionally, data read-outs from important clinical trials are anticipated in H1 2024, potentially paving the way for commercial launches. The company emphasizes its commitment to improving treatment options for cancer patients and engaging with healthcare professionals to raise awareness of LGSOC.
Read more →VSTM▼ -5.1%on this news
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5 th Annual RAS-Targeted Drug Development Summit Preclinical and Clinical Presentations Include Update on FRAME Study Low-Grade Serous Ovar
Verastem Oncology presented updates on its investigational combination therapies, avutometinib and defactinib, at the 5th Annual RAS-Targeted Drug Development Summit. The FRAME study revealed a 42% overall response rate in patients with low-grade serous ovarian cancer, with even higher rates observed in those with KRAS mutations. The presentations also emphasized the promising potential of these therapies to improve treatment outcomes, particularly following the recent FDA Breakthrough Therapy designation. Further clinical evaluations are ongoing to solidify these findings and assess broader applicability.
Read more →VSTMCorporate Presentation September 2023 2 Disclaimers This presentation includes forward-looking statements about, among other things, Verastem Oncology's programs and product candidates, including anticipated regulatory s
Verastem Inc. has presented data supporting the clinical evaluation of its candidate Avutometinib in combination with various therapies across different types of cancers, including KRAS mutant colorectal cancer and melanoma. The data highlights the potential for Avutometinib to work in synergy with established treatments, offering pathways for new therapies. The ongoing trials are anticipated to yield results in the second half of 2023, which could contribute significantly to treatment options for patients with specific mutations. Overall, the management team's expertise and the promising data position Verastem well within the current biopharmaceutical landscape.
Read more →VSTMVerastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
Verastem Oncology announced the promotion of Dan Paterson to Chief Executive Officer, effective August 1, 2023. He succeeds Brian Stuglik, who will retire but remain on the Board of Directors. Paterson has been with the company since 2011 and has played a crucial role in its development of oncology treatments. Under his leadership, the company aims to advance its clinical programs, particularly focusing on the treatment of recurrent low-grade serous ovarian cancer with its lead compound, avutometinib.
Read more →VSTMCorporate Presentation June 2023 2 Disclaimers This presentation includes forward - looking statements about, among other things, Verastem Oncology's programs and product candid ates, including anticipated regulatory sub
Verastem Oncology provided insights into its corporate presentation June 2023, detailing forward-looking statements regarding its oncology programs and product candidates, including expected regulatory submissions and performance metrics. The company emphasizes the promising clinical activities of its lead candidates, avutometinib and defactinib, particularly in relation to RAS pathway-driven cancers. Despite these optimistic projections, the presentation acknowledges potential risks including adverse safety events and regulatory uncertainties that could impact commercialization. Verastem is also focusing on patent protection and good financial health to support its development goals.
Read more →VSTMVerastem Oncology Announces Reverse Stock Split BOSTON, MA
Verastem Oncology has announced a 1-for-12 reverse stock split of its common stock, effective May 31, 2023. This decision follows stockholder approval at the company's Annual Meeting on May 15, 2023, and is intended to raise the per share trading price to meet Nasdaq listing standards. The reverse split will reduce the total number of outstanding shares significantly while allowing stockholders to receive cash for any fractional shares. The company emphasizes its ongoing commitment to developing new oncology treatments.
Read more →VSTMUpdated Data from Part A of Verastem Oncology s RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib Data Build on Brea
Verastem Oncology announced updated data from Part A of its RAMP 201 trial, reporting a 45% objective response rate in patients with recurrent low-grade serous ovarian cancer treated with the combination of avutometinib and defactinib. The results indicate substantial tumor shrinkage in 86% of evaluable patients, reinforcing the therapy's potential as a new treatment option. The study aims to assess both KRAS mutant and wild type LGSOC responses, as well as finalize plans for a randomized confirmatory trial. Findings will be presented at the upcoming American Society of Clinical Oncology Annual Meeting.
Read more →VSTM▲ +8.6%on this news
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers Avutometinib + Defactinib Combination Advancing in Recurr
Verastem Oncology has outlined its strategic priorities for 2023, focusing on the advancement of its investigational drug, avutometinib, for RAS pathway-driven cancers. The company highlights the positive interim results from the RAMP 201 trial for recurrent low-grade serous ovarian cancer (LGSOC), coupled with its plans for additional confirmatory studies. Following the recent financing, Verastem aims to strengthen its development program, with key initiatives for KRAS G12C mutant NSCLC and metastatic pancreatic cancer. Overall, Verastem is positioned to enhance treatment options for patients with high unmet medical needs.
Read more →VSTMLGSOC Program Update
Verastem Oncology provided an update on its LGSOC program, particularly focusing on the investigational drug avutometinib. This therapy has received Breakthrough Therapy Designation for treating recurrent low-grade serous ovarian cancer, demonstrating a favorable safety profile and potential for effective combination therapies. Despite promising data, the program faces substantial risks regarding development and commercialization, particularly concerning adverse events and intellectual property issues. The unmet medical need in this cancer type is significant, underscoring the importance of continued research and regulatory efforts.
Read more →VSTM▼ -5%on this news· ran to -16% by day 3
Verastem Oncology Appoints Rob Gagnon to Board of Directors BOSTON
Verastem Oncology Appoints Rob Gagnon to Board of Directors BOSTON - December 15, 2022 - Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Robert Gagnon to its Board of D
Read more →VSTMVerastem Oncology Appoints Anil Kapur to Board of Directors BOSTON
Verastem Oncology Appoints Anil Kapur to Board of Directors BOSTON - October 20, 2022 - Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Direc
Read more →VSTM▼ -34.6%on this news
Corporate Presentation October 2022 2 Safe Harbor Statement This presentation includes forward - looking statements about, among other things, Verastem Oncology's programs and product candidates, including anticipated re
(now On - Q - ity) PharMetrics (now IMS), Axion Head of Cancer Biology OSI (now Astellas) Schering - Plough Rob Gagnon Chief Business and Financial Officer CFO Harvard Bioscience, Clean Harbors VP of Finance Biogen Idec Hagop Youssoufian, MSc, M.D. Head of Medical Strategy CMO, B
Read more →VSTM▲ +7.6%on this news
Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress Company Reported Interim Findings from RAMP 201 Trial of VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer; C
Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress Company Reported Interim Findings from RAMP 201 Trial of VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer; Continued Evaluation of Both Monotherapy and Combination The
Read more →VSTM▼ -8.3%on this news
Corporate Presentation June 2022 2 Safe Harbor Statement This presentation includes forward - looking statements about, among other things, Verastem Oncology's programs and product candidates, including anticipated regul
(now On - Q - ity) PharMetrics (now IMS), Axion Head of Cancer Biology OSI (now Astellas) Schering - Plough Rob Gagnon Chief Business and Financial Officer CFO Harvard Bioscience, Clean Harbors VP of Finance Biogen Idec Hagop Youssoufian, MSc, M.D. Head of Medical Strategy CMO, B
Read more →VSTM▲ +10.9%on this news· ran to +27% by day 1
Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors Company Secures up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC, Providing Addi
Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors Company Secures up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC, Providing Additional Financial Flexibility Expected Cash Runway Through
Read more →VSTMCorporate Presentation January 2022 2 Safe Harbor Statement This presentation includes forward - looking statements about, among other things, Verastem Oncology's programs and product candidates, including anticipated re
(now On - Q - ity) PharMetrics (now IMS), Axion Head of Cancer Biology OSI (now Astellas) Schering - Plough Rob Gagnon Chief Business and Financial Officer CFO Harvard Bioscience, Clean Harbors VP of Finance Biogen Idec Hagop Youssoufian, MSc, M.D. Head of Medical Strategy CMO, B
Read more →VSTMVerastem Oncology Appoints Michelle Robertson to Board of Directors BOSTON
Verastem Oncology Appoints Michelle Robertson to Board of Directors BOSTON - October 26, 2021 - Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of Michelle Robertson t
Read more →VSTMVerastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors BOSTON--(BUSINESS WIRE)
Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors BOSTON--(BUSINESS WIRE)--June 24, 2021-Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today
Read more →VSTMCorporate Presentation May 2021 NASDAQ: VSTM 2 This presentation includes forward-looking statements about, among other things, Verastem Oncology's programs and product candidates, including anticipated regulatory submis
Head of Medical Strategy Principal HR Collaborative Ironwood, ActiveBiotics, Dynogen, Tufts Health Plan CMO, BIND Therapeutics, EVP, Progenics, CMO & EVP, Ziopharm Oncology, SVP, Imclone Global VP & Chief Marketing Officer Lilly Oncology Founding Member Proventus Health Solutions
Read more →VSTMCorporate Presentation February 2021 NASDAQ: VSTM Safe Harbor Statement This presentation includes forward-looking statements about, among other things, Verastem Oncology's products and product candidates, including anti
(now On-Q-ity) PharMetrics (now IMS), Axion Rob Gagnon Chief Business and Financial Officer CFO - Harvard Bioscience, Clean Harbors VP of Finance - Biogen Idec Cathy Carew Chief People & Organizational Strategy Officer Principal - HR Collaborative Ironwood, ActiveBiotics, Dynogen
Read more →VSTMBTIG KOL Event
BTIG KOL Event December 17, 2020 NASDAQ: VSTM 2 PROPERTY OF VERASTEM INC. On Today's Call *On April 23, 2019, we entered into a 4 th Amendment to our existing Agreement with Hercules Capital, Inc. whereas we may borrow up to an aggregate amount of $75.0 mill io n, of which $35.0
Read more →VSTMVerastem Oncology Announces Closing of COPIKTRA (duvelisib) Sale to Secura Bio Verastem Now Focused on Development of VS-6766 and Defactinib Combination in Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell L
Oncology Announces Closing of COPIKTRA (duvelisib) Sale to Secura Bio Verastem Now Focused on Development of VS-6766 and Defactinib Combination in Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Registration-Directed Clinical Trials in LGSOC and KRA
Read more →VSTMVerastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2 nd Annual RAS-Targeted Drug Development Summit Preliminary Data on VS-6766 and Defactinib Combination Continues to Show Encouraging
Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit Preliminary Data on VS-6766 and Defactinib Combination Continues to Show Encouraging Response Rates, Durability and a Favorable Safety Profile
Read more →VSTMVerastem Oncology Signs Definitive Agreement to Sell COPIKTRA (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors Verastem Will Receive $70 Million Up-Front with
Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors Will Receive $70 Million Up-Front with Total Deal Value up to $311 Million, Plus Double-Digit Sales Royal
Read more →VSTMPROPERTY OF VERASTEM, INC. 1 Addressing RAS Pathway Blockade & Resistance VS - 6766 & Defactinib Combination Data in KRAS Mutant Solid Tumors Investor Conference Call and Webcast
PROPERTY OF VERASTEM, INC. 1 Addressing RAS Pathway Blockade & Resistance VS - 6766 & Defactinib Combination Data in KRAS Mutant Solid Tumors Investor Conference Call and Webcast April 27, 2020 NASDAQ: VSTM PROPERTY OF VERASTEM, INC. 2 2 Speakers Verastem Oncology Brian Stuglik
Read more →VSTMVerastem Oncology Appoints John H. Johnson to its Board of Directors BOSTON, MA
Verastem Oncology Appoints John H. Johnson to its Board of Directors BOSTON, MA - April 23, 2020 -Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer
Read more →VSTMVerastem Oncology Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences Investors BOSTON--(BUSINESS WIRE)—
Verastem Oncology Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences Investors BOSTON--(BUSINESS WIRE) February 28, 2020 -- Verastem, Inc. (NASDAQ: VSTM) (the Company ), today announced that it has agreed to sell approximately 46.5 million
Read more →VSTMPROPERTY OF VERASTEM, INC. 1 Corporate Overview | J.P. Morgan Healthcare Conference |
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. 51 PROPERTY OF VERASTEM, INC. NOT FOR DISTRIBUTION OR DISS
Read more →VSTMVerastem Oncology Announces Private Exchange of Approximately $114.3 Million of its 5.00% Convertible Senior Notes due 2048 for 5.00% Convertible Senior Second Lien Notes Due 2048 BOSTON, MA –
Verastem Oncology Announces Private Exchange of Approximately $114.3 Million of its 5.00% Convertible Senior Notes due 2048 for 5.00% Convertible Senior Second Lien Notes Due 2048 BOSTON, MA November 12, 2019 Verastem, Inc. (NASDAQ: VSTM) (the Company ) today announced that it h
Read more →VSTMVerastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress Company Reports $9 Million in Total Revenue, including $4.0 Million in Net Product Revenue from COPIKTRA®; Reaffirms FY201
Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress Company Reports $9 Million in Total Revenue, including $4.0 Million in Net Product Revenue from COPIKTRA ; Reaffirms FY2019 Revenue Guidance Cash, Cash Equivalents and Short-Term Investme
Read more →VSTMVerastem Oncology Appoints Brian Stuglik as Chief Executive Officer BOSTON, MA –
Verastem Oncology Appoints Brian Stuglik as Chief Executive Officer BOSTON, MA July 29, 2019 Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and qual
Read more →VSTMVerastem Oncology Announces Leadership Changes
Verastem Oncology Announces Leadership Changes Robert Forrester Stepping Down From His Roles as President and Chief Executive Officer Chief Operating Officer, Dan Paterson Appointed President Chief Financial Officer, Rob Gagnon, Expanding Role to Include Chief Business Officer
Read more →VSTMVerastem Oncology Announces Amendment to Refinance Hercules Loan Facility New Terms Provide for Lower Interest Rate and Longer Interest-Only Payment Period BOSTON, MA –
Verastem Oncology Announces Amendment to Refinance Hercules Loan Facility New Terms Provide for Lower Interest Rate and Longer Interest-Only Payment Period BOSTON, MA April 23, 2019 Verastem, Inc. (Nasdaq: VSTM) operating as Verastem Oncology, (or the Company ), focused on deve
Read more →VSTMVerastem Oncology Announces Executive Leadership Appointments and Changes Gina Consylman Joining Board of Directors Hagop Youssoufian, MSc, MD Transitioning to Head of Medical Strategy Kirk Taylor, MD, Appointed Senior V
Verastem Oncology Announces Executive Leadership Appointments and Changes Gina Consylman Joining Board of Directors Hagop Youssoufian, MSc, MD Transitioning to Head of Medical Strategy Kirk Taylor, MD, Appointed Senior Vice President, Medical Affairs Strategy and Operations B
Read more →VSTMVerastem, Inc. 5.00% Convertible Senior Notes due 2048 Placement Agent Agreement
5.00% Convertible Senior Notes due 2048 Placement Agent Agreement Lazard Fr res & Co. LLC 30 Rockefeller Plaza New York, New York 10112 Ladies and Gentlemen: 1. Introduction. Verastem, Inc., a Delaware corporation (the Company ), proposes, subject to the terms and condition
Read more →VSTMVerastem Oncology Receives FDA Approval of COPIKTRA (duvelisib) capsules Company to host conference call today at 4:30pm
Verastem Oncology Receives FDA Approval of COPIKTRA (duvelisib) capsules Company to host conference call today at 4:30pm ET BOSTON, MA September 24, 2018 Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to impr
Read more →VSTMVerastem Oncology Appoints Robert E. Gagnon as Chief Financial Officer BOSTON, MA
Verastem Oncology Appoints Robert E. Gagnon as Chief Financial Officer BOSTON, MA August 29, 2018 Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients,
Read more →VSTMPURCHASE AGREEMENT This PURCHASE AGREEMENT (this Agreement ) is dated as of
This PURCHASE AGREEMENT (this Agreement ) is dated as of June 14, 2018, between Verastem, Inc., a Delaware corporation (the Company ), and the purchasers identified on the signature pages hereto (collectively, the Purchaser ). WHEREAS, the Purchaser desires to subscribe for, and
Read more →VSTMVerastem Announces Increased Hercules Debt Facility Increases Borrowing Limit to $50 Million Over the Next 15 Months, Through Potential Approval and Commercial Launch of Duvelisib BOSTON, MA
Verastem Announces Increased Hercules Debt Facility Increases Borrowing Limit to $50 Million Over the Next 15 Months, Through Potential Approval and Commercial Launch of Duvelisib BOSTON, MA January 4, 2018 Verastem, Inc. (Nasdaq: VSTM), focused on discovering and developing dr
Read more →VSTMInformation Relating to Part II. Item 14. - Other Expenses of Issuance and Distribution The expenses in connection with the offer and sale of shares of common stock of Verastem, Inc., registered pursuant to the Registrat
Information Relating to Part II. Item 14. - Other Expenses of Issuance and Distribution The expenses in connection with the offer and sale of shares of common stock of Verastem, Inc., registered pursuant to the Registration Statement on Form S-3 (Registration No. 333-217048) fi
Read more →VSTMVerastem Pays Milestone Payment to Infinity Pharmaceuticals BOSTON, MA
Verastem Pays Milestone Payment to Infinity Pharmaceuticals BOSTON, MA October 17, 2017 Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced payment of a $6 million milestone to
Read more →VSTMCORPORATE OVERVIEW NASDAQ: VSTM SEPTEMBER 18, 2017 FORWARD-LOOKING STATEMENTS This presentation and other matters discussed today, or answers that may be given today, include forward-looking statements about Verastem s s
CORPORATE OVERVIEW NASDAQ: VSTM SEPTEMBER 18, 2017 FORWARD-LOOKING STATEMENTS This presentation and other matters discussed today, or answers that may be given today, include forward-looking statements about Verastem s strategy, future plans and prospects, including statements r
Read more →VSTMVerastem Expands Duvelisib Development Program to Include Peripheral T-Cell Lymphoma Duvelisib Receives Fast Track Designation from FDA in PTCL; Company to Initiate a Phase 2 Clinical Trial by Year End 2017 Former Chief
Verastem Expands Duvelisib Development Program to Include Peripheral T-Cell Lymphoma Duvelisib Receives Fast Track Designation from FDA in PTCL; Company to Initiate a Phase 2 Clinical Trial by Year End 2017 Former Chief Marketing Officer, Lilly Oncology, Brian Stuglik Joins the
Read more →VSTMVerastem Names Julie B. Feder as Chief Financial Officer BOSTON, MA
Verastem Names Julie B. Feder as Chief Financial Officer BOSTON, MA July 11, 2017 Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Julie B. Feder as Chief
Read more →VSTMVerastem Appoints Eric K. Rowinsky to the Board of Directors BOSTON, MA
Verastem Appoints Eric K. Rowinsky to the Board of Directors BOSTON, MA May 2, 2017 Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Eric K. Rowinsky, MD
Read more →VSTMVerastem Licenses Duvelisib from Infinity Pharmaceuticals Transaction Adds Complementary Late-Stage Product Candidate from a Clinically Validated Drug Class to Verastem s Pipeline Duvelisib Has Demonstrated Clinical Acti
Verastem Licenses Duvelisib from Infinity Pharmaceuticals Transaction Adds Complementary Late-Stage Product Candidate from a Clinically Validated Drug Class to Verastem s Pipeline Duvelisib Has Demonstrated Clinical Activity in Lymphoid Malignancies License of Duvelisib Aligns
Read more →VSTMVerastem Announces Changes to its Board of Directors BOSTON, MA
Verastem Announces Changes to its Board of Directors BOSTON, MA June 14, 2016 Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced several changes to the Company s Board of Directors. Michael Kauffman, MD, PhD, who has serve
Read more →VSTMVerastem Names Gregory I. Berk, MD as Chief Medical Officer - Announces Additional Key Executive Management Appointments and Changes - BOSTON, MA
Verastem Names Gregory I. Berk, MD as Chief Medical Officer - Announces Additional Key Executive Management Appointments and Changes - BOSTON, MA April 18, 2016 Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the appoin
Read more →VSTMVerastem Reports Year-End 2015 Financial Results BOSTON, MA
Verastem Reports Year-End 2015 Financial Results BOSTON, MA March 3, 2016 Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the year ended December 31, 2015, and also provided an overview of certain c
Read more →VSTMCORPORATE OVERVIEW NASDAQ: VSTM
CORPORATE OVERVIEW NASDAQ: VSTM January 7, 2016 Page FORWARD-LOOKING STATEMENTS This presentation, and other matters discussed today, or answers that may be given to questions asked, includes forward-looking statements about the Company's strategy, future plans and prospects, in
Read more →VSTMVerastem Reports Third Quarter 2015 Financial and Corporate Results BOSTON (BUSINESS WIRE)
Verastem Reports Third Quarter 2015 Financial and Corporate Results BOSTON (BUSINESS WIRE) Nov. 9, 2015 Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for t
Read more →VSTMVerastem Stops Enrollment due to Futility in the COMMAND Study of VS-6063 for the Treatment of Malignant Pleural Mesothelioma No difference in VS-6063 versus placebo in either the intent to treat population or patients w
Verastem Stops Enrollment due to Futility in the COMMAND Study of VS-6063 for the Treatment of Malignant Pleural Mesothelioma No difference in VS-6063 versus placebo in either the intent to treat population or patients with Merlin-low tumors Company to Host Conference Call Toda
Read more →VSTMVerastem Issues Statement Regarding WCLC Presentations BOSTON, MA
Verastem Issues Statement Regarding WCLC Presentations BOSTON, MA August 26, 2015 Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today issued the following statement in response to inquirie
Read more →VSTMVerastem Reports Year-End 2014 Financial Results COMMAND Interim Analysis Expected Second Quarter 2015 BOSTON, MA
Verastem Reports Year-End 2014 Financial Results COMMAND Interim Analysis Expected Second Quarter 2015 BOSTON, MA Mar. 10, 2015 Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today report
Read more →VSTMVerastem Provides Year-End 2014 Update and Outlook for 2015 -COMMAND Study Currently On Track for Completion of Enrollment by Year-End 2015- -Signals of Clinical Activity in all Programs Targeting Cancer Stem Cells Have
Verastem Provides Year-End 2014 Update and Outlook for 2015 -COMMAND Study Currently On Track for Completion of Enrollment by Year-End 2015- -Signals of Clinical Activity in all Programs Targeting Cancer Stem Cells Have Been Observed- -Management to Host Conference Call Today
Read more →VSTMVerastem Appoints Daniel Paterson as Chief Operating Officer BOSTON, MA
Verastem Appoints Daniel Paterson as Chief Operating Officer BOSTON, MA December 18, 2014 Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that Daniel Paterson, Chief Business
Read more →VSTMDr. Paul A. Friedman Joins Verastem Board of Directors CAMBRIDGE, MA
Dr. Paul A. Friedman Joins Verastem Board of Directors CAMBRIDGE, MA May 12, 2014 Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the appointment of Paul A. Friedman, M.D. to
Read more →VSTMTimothy J. Barberich Joins Verastem Board of Directors Cambridge, MA
Timothy J. Barberich Joins Verastem Board of Directors Cambridge, MA March 11, 2014 Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the appointment of Timothy J. Barberich to
Read more →VSTMVerastem Reports Year-End 2013 Financial Results A year of clinical execution: Three small molecule compounds in clinical development including the registration-directed COMMAND study Multiple clinical data readouts anti
Verastem Reports Year-End 2013 Financial Results A year of clinical execution: Three small molecule compounds in clinical development including the registration-directed COMMAND study Multiple clinical data readouts anticipated starting in first half 2014 CAMBRIDGE, MA - Mar.
Read more →VSTMVerastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718 The acquisition reduces milestones and royalties associated with ongoing VS-4718 development CAMBRIDGE, Mass. (BUSINESS WIRE)
Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718 The acquisition reduces milestones and royalties associated with ongoing VS-4718 development CAMBRIDGE, Mass. (BUSINESS WIRE) February 25, 2014 Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing dru
Read more →VSTMVerastem Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass. (BUSINESS WIRE)
Verastem Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass. (BUSINESS WIRE) July 16, 2013 Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it intends to
Read more →VSTMVerastem Appoints Robert Forrester as Chief Executive Officer - Christoph Westphal, M.D., Ph.D., to Transition to Executive Chairman as of
Verastem Appoints Robert Forrester as Chief Executive Officer - Christoph Westphal, M.D., Ph.D., to Transition to Executive Chairman as of July 1, 2013 - -Conference call scheduled for 8:45am ET on Thursday, June 6- Cambridge, MA June 6, 2013 Verastem, Inc., (NASDAQ: VSTM) foc
Read more →VSTMJack Green Joins Verastem as Chief Financial Officer Cambridge, MA
Jack Green Joins Verastem as Chief Financial Officer Cambridge, MA May 14, 2013 Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the appointment of John Jack Green as Chief Financia
Read more →VSTMVerastem Reports Year-End 2012 Financial Results -Advancing clinical development programs targeting cancer stem cells through FAK and PI3K/mTOR inhibition- CAMBRIDGE, MA
Verastem Reports Year-End 2012 Financial Results -Advancing clinical development programs targeting cancer stem cells through FAK and PI3K/mTOR inhibition- CAMBRIDGE, MA - Mar. 27, 2013 Verastem, Inc., (NASDAQ: VSTM), a clinical-stage biopharmaceutical company focused on discov
Read more →VSTMStephen Sherwin, M.D., Joins Verastem Board of Directors CAMBRIDGE, MA
Stephen Sherwin, M.D., Joins Verastem Board of Directors CAMBRIDGE, MA Mar. 6, 2013 Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the a
Read more →VSTMVerastem Promotes Chief Operating Officer Robert Forrester to President
Verastem Promotes Chief Operating Officer Robert Forrester to President CAMBRIDGE, Mass. Jan. 22, 2013 Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cel
Read more →VSTMAlison Lawton and Michael Kauffman Join Verastem Board of Directors
Alison Lawton and Michael Kauffman Join Verastem Board of Directors CAMBRIDGE, Mass. Nov. 26, 2012 Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells,
Read more →VSTMLouise Phanstiel Joins Verastem Board of Directors Cambridge, Mass.
Louise Phanstiel Joins Verastem Board of Directors Cambridge, Mass. September 19, 2012 Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced the appointme
Read more →VSTMVerastem Reports Second Quarter 2012 Financial and Corporate Results CAMBRIDGE, MA
Verastem Reports Second Quarter 2012 Financial and Corporate Results CAMBRIDGE, MA August 13, 2012 Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today repor
Read more →VSTMVerastem Acquires Clinical-Stage FAK Inhibitor from Pfizer CAMBRIDGE, MA
Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer CAMBRIDGE, MA July 11, 2012 Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced an agreement
Read more →VSTMVerastem, Inc. Reports First Quarter 2012 Financial Results CAMBRIDGE, MA
Verastem, Inc. Reports First Quarter 2012 Financial Results CAMBRIDGE, MA May 14, 2012 Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today reported financia
Read more →VSTMVerastem, Inc. Reports Year-End 2011 Financial Results CAMBRIDGE, MA
Verastem, Inc. Reports Year-End 2011 Financial Results CAMBRIDGE, MA - Mar. 14, 2012 Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today reported financial
Read more →Competitive Position
How VSTM ranks across every disease it competes inCompetitive Position is a premium feature
See how VSTM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial